GSK has decided to voluntarily withdraw Juluca (dolutegravir/rilpivirine), the company’s first-ever two-drug regimen of HIV treatment, three years and nine months after it won the permit in Korea.According to the Ministry of Food and Drug Safety, GSK withdrew the permit of Juluca Tab. on Monday.Acco
Janssen Korea and Illumina Korea are considering trimming their payroll, following the moves of other Korean offshoots of multinational pharmaceutical firms.According to industry sources, Janssen Korea is trying to reduce its workforce through an early retirement program (ERP)."I have heard that our
Wells Bio, a subsidiary of Access Bio, said on Tuesday that it has recently obtained approval from the Ministry of Food and Drug Safety (MFDS) for its kit that can diagnose tsutsugamushi bacterial infections.Tsutsugamushi is an acute febrile disease transmitted by larvae of chigger mites carrying ts
It may be safe to say that the development of PARP (Poly ADP-ribose polymerase) inhibitors has changed the treatment environment for ovarian cancer. That’s because the development extended the progression-free survival period and other prognoses of ovarian cancer patients.After it was known that PAR
ImmuneMed has won the approval for the domestic clinical trial of its candidate substance for a Covid-19 cure, hzVCFG-v13 (burfiralimab).Last Friday, the Ministry of Food and Drug Safety gave the go-ahead to Korea's phase 2/3 clinical trial. The company plans to assess the efficacy and safety of the
Yuyu Pharmaceutical unveiled its plans to conduct U.S. and EU clinical trials for using dutasteride to treat androgenetic alopecia (AGA) during the World Congress for Hair Research 2022 held in Melbourne, Australia, from Friday to Monday.The trial aims to improve patient convenience by reducing the
Moderna started to receive recognition as a messenger RNA (mRNA) powerhouse after developing an effective Covid-19 vaccine less than a year after the Covid-19 pandemic first started.However, with the Covid-19 pandemic becoming more of an endemic than a pandemic, both industry watchers and investors
Korean conglomerates are jumping into the bio-industry after seeing success from predecessors, including Samsung and SK.Most recently, Orion Holdings, the holding company of the Orion Group, decided to start the bio business in earnest by establishing Orion Biologics.In a public filing, Orion Holdin
JW Pharmaceutical said on Friday that its oral renal anemia drug, Enaroy (ingredient: enarodustat), obtained license approval from the Ministry of Food and Drug Safety (MFDS).Renal anemia is one of the complications of chronic kidney disease, and is caused by poor differentiation and proliferation o
Celltrion said on Friday that it won the first trial of two patents (Patent No. US 9254338, US 9669069) against Regeneron, a leading biotechnology company in the United States.The lawsuit regards a U.S. patent on the treatment of angiogenic ophthalmic diseases of Eylea (ingredient: aflibercept), an
“Korean biotechnology companies’ scientific quality does not lag behind other countries. However, they fall somewhat short of understanding what the medical community and biotech industry want.”So said Philip Tagari, vice chair for Amgen’s R&D, who visited Korea to attend the “Second KHIDI-AMGEN Sci
To help foster healthcare startups, BMS Korea held the “Seoul BMS Innovation Square Challenge” award ceremony with the Seoul Municipal Government and the Korea Health Industry Development Institute (KHIDI) at Seoul Bio Hub last week.The challenge is an open innovation partnering program pushed joint
Dong-A ST said it has completed the global phase 3 clinical trial of DMB-3115, a biosimilar referencing Janssen’s plaque psoriasis treatment Stelara (ingredient: ustekinumab).The company initially initiated the global phase 3 clinical trial of DMB-3115 in the U.S. in 2021 and expanded it to eight ot
SK Bioscience, one of Korea’s leading vaccine makers, said it donated 3 billion won ($2.2 million) to the International Vaccines Institute (IVI) on Wednesday to advance global vaccine research and development.The donation will be used to support vaccine R&D, equipment, and device purchases, it added
CHA Vaccine Institute announced it is developing a mixed vaccine to prevent Covid-19 and influenza at the 2022 Hwasun International Vaccine Forum last Friday.The research institute said the combination vaccine aims to improve convenience and preventive effects for the elderly. The candidate substanc
LegoChem Bioscience said it signed an antibody-drug conjugate (ADC) joint research and development agreement with NextCure, a U.S. pharmaceutical company.Under the accord, the two companies plan to discover new ADC anticancer drugs by utilizing Next Cure's B7-H4 antibody and LegoChem's ADC platform
Roche Korea’s Tecentriq (atezolizumab) has expanded its indication to postoperative adjuvant therapy for the first time among lung cancer immunotherapies but fell short of expectations, industry watchers said on Wednesday.Last Friday, the Ministry of Food and Drug Safety approved the use of Tecentri
Middle Eastern countries including such as the United Arab Emirates (UAE) and Saudi Arabia are becoming major importers of Korean biopharmaceutical products.According to the Korea Customs Service's import and export statistics on Tuesday, exports of medical supplies, including pharmaceuticals and di
United Pharm is about to apply for the regulatory approval of a combo therapy, which combines the antithrombotic ingredient of cilostazol with the dyslipidemia component of rosuvastatin.Industry insiders pay attention to whether Korea United Pharm, which emerged as a significant player in the antith
Dx&Vx, a Korean molecular diagnostics company, said Wednesday that it recorded 8.6 billion won ($ 6.4 million) in sales in the third quarter, up 82.8 percent from the same period in 2021.The company also registered 412.2 million and 620.8 million won in operating and net profit, down 56.5 and 67.8 p